[Fundamental and clinical studies on XXXX in the perinatal period].

@entity281 @entity8353 @entity5505
Fundamental and clinical studies were carried out on @entity5505 ( @entity8353 ) in the perinatal period, and the results obtained were summarized below. Following bolus intravenous injection of @entity8353 2 g, maternal serum concentrations of @entity8353 were as high as 145.3 +/- 17.2 micrograms/ml (mean +/- S.D.) at about 10 minutes, and then gradually decreased to 46.7 micrograms/ml at 2 hours, 5.31 micrograms/ml at 5 hours and 4 minutes, and 1.54 micrograms/ml at 11 hours and 10 minutes. The @entity8353 was detected in umbilical cord serum immediately after the administration, and concentrations were 31.0 +/- 1.54 micrograms/ml at about 10 minutes. Although the concentrations gradually decreased thereafter, they were higher than those in maternal serum at 3 hours and later and was 3.00 micrograms/ml at 11 hours and 10 minutes. The @entity8353 was detected in amniotic fluid a little later than in umbilical cord serum, and concentrations of @entity8353 in amniotic fluid were as low as 1.50 +/- 0.67 micrograms/ml at about 10 minutes after the administration. Concentrations then gradually increased to 12.8 micrograms/ml at 2 hours and 26.5 micrograms/ml at 5 hours and 4 minutes, and even at 11 hours and 10 minutes, they were as high as 14.2 micrograms/ml. The above results demonstrated that the transfer of @entity8353 through placental barrier was very rapid and satisfactory. Also, @entity8353 showed good transfer into amniotic fluid, as well as sufficient retention, and was considered to be an effective antibiotic for prophylaxis of both fetal @entity281 .(ABSTRACT TRUNCATED AT 250 WORDS)
